AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) shares traded up 2.9% on Thursday . The company traded as high as $25.69 and last traded at $25.37, with a volume of 834,194 shares. The stock had previously closed at $24.66.

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. reissued a “hold” rating and issued a $37.00 target price on shares of AMAG Pharmaceuticals in a research note on Thursday, May 5th. Raymond James Financial Inc. lowered shares of AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 4th. Jefferies Group reissued a “buy” rating on shares of AMAG Pharmaceuticals in a research note on Wednesday, May 4th. Zacks Investment Research raised shares of AMAG Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Finally, Leerink Swann reissued an “outperform” rating on shares of AMAG Pharmaceuticals in a research note on Saturday, April 16th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. AMAG Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $38.20.

The company has a market capitalization of $877.24 million and a PE ratio of 84.85. The firm’s 50 day moving average is $22.36 and its 200-day moving average is $23.75.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its earnings results on Tuesday, May 3rd. The specialty pharmaceutical company reported $0.94 earnings per share for the quarter, missing the consensus estimate of $1.11 by $0.17. The business had revenue of $117.60 million for the quarter, compared to the consensus estimate of $124.83 million. During the same quarter in the prior year, the firm earned $1.17 EPS. The company’s revenue for the quarter was up 41.9% compared to the same quarter last year. Analysts expect that AMAG Pharmaceuticals Inc. will post $5.20 earnings per share for the current fiscal year.

A number of hedge funds and institutional investors recently modified their holdings of the company. Dimensional Fund Advisors LP raised its position in shares of AMAG Pharmaceuticals by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 397,816 shares of the specialty pharmaceutical company’s stock valued at $12,010,000 after buying an additional 8,435 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in shares of AMAG Pharmaceuticals by 6.6% in the fourth quarter. BNP Paribas Arbitrage SA now owns 62,716 shares of the specialty pharmaceutical company’s stock valued at $1,893,000 after buying an additional 3,903 shares during the period. Principal Financial Group Inc. increased its stake in shares of AMAG Pharmaceuticals by 69.2% in the fourth quarter. Principal Financial Group Inc. now owns 34,282 shares of the specialty pharmaceutical company’s stock valued at $1,034,000 after buying an additional 14,017 shares during the period. Bank of Montreal Can increased its stake in shares of AMAG Pharmaceuticals by 2,782.5% in the fourth quarter. Bank of Montreal Can now owns 75,781 shares of the specialty pharmaceutical company’s stock valued at $2,287,000 after buying an additional 73,152 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. increased its stake in shares of AMAG Pharmaceuticals by 570.4% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 49,608 shares of the specialty pharmaceutical company’s stock valued at $1,498,000 after buying an additional 42,208 shares during the period.

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.